Literature DB >> 1684181

Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum.

R M Hudziak1, A Ullrich.   

Abstract

The HER2 (c-erbB-2) gene encodes a protein, p185HER2, which possesses all of the structural characteristics and functional properties of a growth factor receptor, although its ligand has not yet been well characterized. HER2 is the human homolog of the rat proto-oncogene neu and is closely related to the gene encoding the epidermal growth factor receptor. Amplification of this gene and overexpression have been found to be a prognostic criterion for a 30% subpopulation of human breast cancer patients. In this study, we investigated the role of the transmembrane-spanning sequence in the biosynthesis and localization of p185HER2. A truncation mutant lacking the cytoplasmic and transmembrane domains was glycosylated and efficiently secreted. However, a mutant lacking only the transmembrane-spanning sequence was incompletely glycosylated and failed to reach the cell surface. Unexpectedly, although this deletion mutant was retained in the endoplasmic reticulum membrane, it was still able to transform NIH 3T3 cells when expressed at high levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684181

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Converting a transmembrane receptor to a soluble receptor: recognition domain to effector domain signaling after excision of the transmembrane domain.

Authors:  K M Ottemann; D E Koshland
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase.

Authors:  T Tiganis; A M Bennett; K S Ravichandran; N K Tonks
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

3.  Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.

Authors:  Wenyan Fu; Yuxiao Wang; Yunshan Zhang; Lijuan Xiong; Hiroaki Takeda; Li Ding; Qunfang Xu; Lidong He; Wenlong Tan; Augus N Bethune; Lijun Zhou
Journal:  MAbs       Date:  2014-04-16       Impact factor: 5.857

4.  Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging.

Authors:  Xiaoliang Yang; Zihua Wang; Zhichu Xiang; Dan Li; Zhiyuan Hu; Wei Cui; Lingling Geng; Qiaojun Fang
Journal:  PLoS Comput Biol       Date:  2017-04-13       Impact factor: 4.475

5.  Identification and correction of abnormal, incomplete and mispredicted proteins in public databases.

Authors:  Alinda Nagy; Hédi Hegyi; Krisztina Farkas; Hedvig Tordai; Evelin Kozma; László Bányai; László Patthy
Journal:  BMC Bioinformatics       Date:  2008-08-27       Impact factor: 3.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.